1-8 of 8
Kristina Myhr-Eriksson
Close
Sort by
Journal Articles

Effects of Dasatinib and Interferon-α Combination Treatment on the Immune System in CML

Mette Ilander, PhD, Hanna Lähteenmäki, MSc, Ulla Olsson-Stromberg, MD PhD, Jesper Stentoft, MD PhD, Johan Richter, MD, Perttu Koskenvesa, MD, Martin Höglund, MD PhD, Arta Dreimane, MD PhD, Kimmo Porkka, MD PhD, Tobias Gedde-Dahl, Björn T. Gjertsen, Franz X. Gruber, Leif Stenke, MD PhD, Kristina Myhr-Eriksson, MD, Berit Markevärn, MD, Anna Lubking, MD, Hanne Vestergaard, MD PhD, Lene Udby, MD, Ole Weis Bjerrum, MD, Henrik Hjorth-Hansen, MD PhD, Satu Mustjoki, MD PhD
Journal: Blood
Blood (2016) 128 (22): 627.
https://doi.org/10.1182/blood.V128.22.627.627
Published: 2016
Journal Articles

Prevalence and Characteristics of Survivors from Adult Acute Myeloid Leukemia (AML) in Sweden 2014

Gunnar Juliusson, MD PhD, Vladimir Lazarevic, Petar Antunovic, MD, Asa Rangert Derolf, MDPhD, Hege Garelius, MD, Sören Lehmann, Prof, Kristina Myhr-Eriksson, MD, Lars Möllgård, MDPhD, Bertil Uggla, MDPhD, Anders Wahlin, Prof, Lovisa Wennström, MD PhD, Martin Höglund, Ass Prof
Journal: Blood
Blood (2015) 126 (23): 4888.
https://doi.org/10.1182/blood.V126.23.4888.4888
Published: 2015
Journal Articles

Safety and Efficacy of Addition of Pegylated Interferon alpha2b to Standard Dose Dasatinib in Newly Diagnosed Chronic Phase CML Patients

Henrik Hjorth-Hansen, MD PhD, Jesper Stentoft, Johan Richter, MD PhD, Perttu Koskenvesa, MD, Arta Dreimane, MD, Kimmo Porkka, MD PhD, Tobias Gedde-Dahl, MDPhD, Bjorn Gjertsen, MD PhD, Franz X. Gruber, MDPhD, Martin Hoglund, MD PhD, Anna Lubking, MD, Kristina Myhr-Eriksson, MD, Berit Markevärn, Hanne Vestergaard, MDPhD, Ole Weis Bjerrum, MDPhD, Leif Stenke, MDPhD, Satu Mustjoki, MD PhD, Ulla Stromberg, MDPhD
Journal: Blood
Blood (2015) 126 (23): 477.
https://doi.org/10.1182/blood.V126.23.477.477
Published: 2015
Journal Articles

Allogeneic Transplantation in First Remission Improves Outcome in Secondary Acute Myeloid Leukemia

Christer Nilsson, MD, Erik Hulegårdh, MD, Vladimir Lazarevic, MD, Hege Garelius, MD, Asa Rangert Derolf, MDPhD, Lars Möllgård, MDPhD, Lovisa Wennström, MD PhD, Bertil Uggla, MD PhD, Petar Antunovic, MD, Kristina Myhr-Eriksson, MD, Anders Wahlin, MD PhD, Martin Höglund, MDPhD, Gunnar Juliusson, MD PhD, Dick Stockelberg, MD PhD, Lehmann Soren, MD PhD
Journal: Blood
Blood (2014) 124 (21): 281.
https://doi.org/10.1182/blood.V124.21.281.281
Published: 2014
Journal Articles

Improved Survival of Patients with Acute Myeloid Leukemia Following Implementation of Swedish National Guidelines: Results from the AML Registry 1997-2013

Gunnar Juliusson, MD PhD, Vladimir Lazarevic, MD, Sören Lehmann, MD PhD, Åsa Rangert Derolf, MD PhD, Lars Möllgård, MDPhD, Hege Garelius, MD, Lovisa Wennström, MD PhD, Bertil Uggla, MD PhD, Petar Antunovic, MD, Kristina Myhr-Eriksson, MD, Anders Wahlin, MD PhD, Martin Höglund, MDPhD
Journal: Blood
Blood (2014) 124 (21): 2269.
https://doi.org/10.1182/blood.V124.21.2269.2269
Published: 2014
Journal Articles

Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry

Martin Höglund, Fredrik Sandin, Karin Hellström, Mats Björeman, Magnus Björkholm, Mats Brune, Arta Dreimane, Marja Ekblom, Sören Lehmann, Per Ljungman, Claes Malm, Berit Markevärn, Kristina Myhr-Eriksson, Lotta Ohm, Ulla Olsson-Strömberg, Anders Själander, Hans Wadenvik, Bengt Simonsson, Leif Stenke, Johan Richter
Journal: Blood
Blood (2013) 122 (7): 1284–1292.
https://doi.org/10.1182/blood-2013-04-495598
Published: 2013
Journal Articles

Combination of pegylated IFN-α2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia

Clinical Trials & Observations
Bengt Simonsson, Tobias Gedde-Dahl, Berit Markevärn, Kari Remes, Jesper Stentoft, Anders Almqvist, Mats Björeman, Max Flogegård, Perttu Koskenvesa, Anders Lindblom, Claes Malm, Satu Mustjoki, Kristina Myhr-Eriksson, Lotta Ohm, Anu Räsänen, Marjatta Sinisalo, Anders Själander, Ulla Strömberg, Ole Weiss Bjerrum, Hans Ehrencrona, Franz Gruber, Veli Kairisto, Karin Olsson, Fredrik Sandin, Arnon Nagler, Johan Lanng Nielsen, Henrik Hjorth-Hansen, Kimmo Porkka, for the Nordic CML Study Group
Journal: Blood
Blood (2011) 118 (12): 3228–3235.
https://doi.org/10.1182/blood-2011-02-336685
Published: 2011
Journal Articles

A Randomized Phase II Study Comparing Imatinib and the Combination of Imatinib and Pegylated Interferon Alpha-2b in Newly Diagnosed Non-High Risk Chronic Myeloid Leukemia (CML) Patients in Complete Hematological Remission After Imatinib Induction Therapy.

Bengt Simonsson, MD, Tobias Gedde-Dahl, MD, Berit Markevärn, MD, Kari Remes, MD, Jesper Stentoft, MD, Anders Almqvist, MD, Mats Björeman, MD, Max Flogegård, MD, Heikki Hallman, MD, Perttu Koskenvesa, MD, Anders Lindblom, MD, Claes Malm, MD, Satu Mustjoki, MD, Kristina Myhr-Eriksson, MD, Anu Räsänen, MD, Marjatta Sinisalo, MD, Risto Sippola, MD, Anders Själander, MD, Ulla Strömberg, MD, Ole Weiss Bjerrum, MD, Hans Ehrencrona, MD, Franz Gruber, MD, Veli Kairisto, MD, Karin RN Olsson, Arnon Nagler, MD, Johan Lanng Nielsen, MD, Henrik Hjorth-Hansen, MD, Kimmo Porkka, MD, for the Nordic CML Study Group (NCMLSG)
Journal: Blood
Blood (2009) 114 (22): 3280.
https://doi.org/10.1182/blood.V114.22.3280.3280
Published: 2009